A Rollover Protocol for Subjects Previously Treated With AGS-003
NCT01482949
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
2
Enrollment
INDUSTRY
Sponsor class
Stopped
Lack of efficacy
Conditions
Renal Cell Carcinoma
Interventions
DRUG:
AGS-003
Sponsor
Argos Therapeutics